Section 1 Contents President’s Report 2

First Page		Document Content
Date: 2010-09-30 20:15:47 Neutron facilities Australian Nuclear Science and Technology Organisation Nuclear energy in Australia Nuclear power in Australia High Flux Australian Reactor Ann Henderson-Sellers Radioligand Positron emission tomography Epidermal growth factor receptor Nuclear technology Medicine Nuclear physics		Section 1 Contents President’s Report 2 Add to Reading List Source URL: www.ainse.edu.au Download Document from Source Website File Size: 1,27 MB Share Document on Facebook

	AbstractProspective multicenter phase II study of the anti-EGFR (epidermal growth factor receptor) antibody panitumumab (P) in patients with platinum pre-treated, advanced head and neck squamous cell cancer (HNSCC DocID: 1rVAJ - View Document
	UNIVERSITÄTSKLINIKUM Schleswig-Holstein Immuntherapie des Glioblastoms Sampson et al. - Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor DocID: 1rgeq - View Document
	Abstract ErbB2 overexpression gives rise to a highly invasive, aggressive phenotype associated with an enlarged lysosomal compartment and increased activity of the lysosomal proteases, cysteine cathepsins. We have recent DocID: 1rdcC - View Document
	Wrangling Phosphoproteomic Data to Elucidate Cancer Signaling Pathways Mark L. Grimes1*, Wan-Jui Lee2, Laurens van der Maaten2, Paul Shannon3 1 Division of Biological Sciences, University of Montana, Missoula, Montana, U DocID: 1qMPs - View Document
	ZAI Lab and Hanmi execute a license agreement to develop novel EGFR targeted therapy for lung cancer in China Shanghai, China and Seoul, Korea, 23th November 2015 – ZAI Lab Limited and Hanmi Pharm. Co., Ltd. announced DocID: 1qm1i - View Document